Bone loss that can lead to osteoporosis and fractures is a major problem for cancer patients who receive chemotherapy and radiation. Since the hormone estrogen plays an important role in maintaining bone health, bone loss ...
Jan 13, 2020
0
14
If you want to predict which breast cancer patients will most likely stop taking aromatase inhibitors, check out their own responses to the health questions patients commonly answer in cancer clinical trials, according to ...
Dec 13, 2019
0
1
A new approach to treat advanced breast cancer shuts down the growth of cells that become resistant to standard hormone therapy, according to Duke Cancer Institute animal studies.
Oct 23, 2019
0
172
The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians offer risk-reducing medications to women at increased risk for breast cancer and at low risk for adverse medication effects. These recommendations ...
Sep 04, 2019
0
2
Tart cherry reduces the musculoskeletal effects of aromatase inhibitors in patients with non-metastatic breast cancer, according to new findings from a clinical trial by researchers at Marshall University Joan C. Edwards ...
Jun 10, 2019
0
0
The early-stage research, led by scientists from Imperial College London and The Institute of Cancer Research, London, identified a genetic 'switch' in breast cancer cells that boosts the production of a type of internal ...
May 30, 2019
0
351
The FRAX tool takes into account certain factors to determine the risk of bone fracture in the general population. In a Journal of Bone and Mineral Research study, the tool was effective at determining fracture risk for women ...
May 09, 2019
0
1
In 2017, the German Institute for Quality and Efficiency in Health Care (IQWiG) already examined the advantages and disadvantages of ribociclib in combination with an aromatase inhibitor versus the appropriate comparator ...
Apr 17, 2019
0
2
Vaginal dryness and painful intercourse are some of the more common adverse events of post-breast cancer treatment therapies and often lead to sexual dissatisfaction and an overall lower quality of life (QOL). However, a ...
Apr 17, 2019
0
0
(HealthDay)—U.S. Food and Drug Administration approval of Ibrance (palbociclib) capsules has been widened to include men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic ...
Apr 06, 2019
0
3
